Background. Non-small cell lung cancer patients with epidermal growth factor receptor
(EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor …

Background Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-
cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine …

BACKGROUND Activating mutations in the epidermal growth factor receptor (EGFR) in non–
small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to …

Somatic mutations introduced into the epidermal growth factor receptor (EGFR) gene in non‐
small‐cell lung cancer (NSCLC) are important factors to determine therapeutic responses to …

Introduction: Mutation of the epidermal growth factor receptor (EGFR) gene can predict the
efficacy of EGFR-tyrosine kinase inhibitors. Different mutations have been shown to co-occur …

Introduction Epidermal growth factor receptor (EGFR) mutations are strong determinants of
tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancers (NSCLCs) …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

Background. Epidermal growth factor receptor (EGFR) mutations are usually detected in
lung adenocarcinoma and are associated with a response to EGFR tyrosine kinase …

Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Introduction The discovery that somatic mutations in the epidermal growth factor receptor
(EGFR) gene are associated with sensitivity to the EGFR tyrosine kinase inhibitors (TKIs) in …